Compare Inovio Pharmaceuticals Inc (INO) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

Inovio Pharmaceuticals IncTrade

Invesco NASDAQ 100 ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Invesco NASDAQ 100 ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Invesco NASDAQ 100 ETF trades at $292.11. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	INO	QQQM
Market Cap	$89.27M	—
Sector	Health	Broad Market / Factor
52-Week High	$2.87	$307.23
52-Week Low	$1.05	$228.02
Enterprise Value	$60.28M	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

Invesco NASDAQ 100 ETF

QQQM trades at $286.58 with minimal daily movement (+0.09%), reflecting a bearish technical signal amid neutral oscillators. The ETF's lower 0.15% expense ratio compared to QQQ attracts long-term growth investors, while recent Nasdaq-100 inclusion of SpaceX (1% weighting) adds diversification. Support levels cluster near $285-$283, with resistance at $288-$292.

Outlook remains tied to tech sector performance, with AI infrastructure spending by holdings like Amazon ($200B annual CapEx guidance) as a key catalyst. Risks include stretched valuations and rising AI competition. The bearish technical bias suggests near-term consolidation, but the fund's cost efficiency supports long-term growth exposure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INO

View details →

QQQM

Investors poured billions into South Korea ETFs and semiconductors amid market shifts last week.ETF Trends · 1 day agoBullish Invesco Nasdaq 100 ETF (QQQM) hits $100B AUM, remains top growth index fund despite new cheaper rivals.ETF Trends · 1 day agoBullish Four ETFs near $100B milestone, highlighting investor demand for growth, dividends, safety, and diversification.ETF Trends · 1 day agoBullish View details →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.